Progress toward HIV eradication: Case reports, current efforts, and the challenges associated with cure

Annual Review of Medicine

Volumn 67, Issue , 2016, Pages 215-228

  Martin, Alyssa R ^a   Siliciano, Robert F ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

Early treatment; Genome editing; HIV 1; Persistence; Shock and kill; Vaccine

Indexed keywords

ANTIRETROVIRUS AGENT; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

ARTICLE; CASE REPORT; CD4+ T LYMPHOCYTE; CLINICAL RESEARCH; ERADICATION THERAPY; GENE THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; REMISSION; VACCINATION; VIRAL GENETICS; VIRUS LATENCY; VIRUS REPLICATION; DISEASE ERADICATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNOLOGY; ISOLATION AND PURIFICATION; SECONDARY PREVENTION; VIROLOGY; VIRUS DNA CELL DNA INTERACTION;

AIDS VACCINES; ANTI-HIV AGENTS; CD4-POSITIVE T-LYMPHOCYTES; DISEASE ERADICATION; GENETIC THERAPY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIV; HIV INFECTIONS; HUMANS; SECONDARY PREVENTION; VIRUS INTEGRATION;

EID: 84954551799     PISSN: 00664219     EISSN: 1545326X     Source Type: Book Series    
DOI: 10.1146/annurev-med-011514-023043     Document Type: Article

References (82)

1. Antiretroviral Therapy Cohort Collaboration. (2008). Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet 372(9635): 293-99
2. Al-Dakkak I, Patel S, McCann E, et al. (2013). The impact of specificHIV treatment-related adverse events on adherence to antiretroviral therapy: a systematic review and meta-Analysis. AIDS Care 25(4): 400-14
3. Bangsberg DR, Acosta EP, Gupta R, et al. (2006). Adherence-resistance relationships for protease and non-nucleoside reverse transcriptase inhibitors explained by virological fitness. AIDS 20(2): 223-31
4. Deeks SG, Tracy R, Douek DC. (2013). Systemic effects of inflammation on health during chronic HIV infection. Immunity 39(4): 633-45
5. Harrigan PR, Whaley M, Montaner JS. (1999). Rate of HIV-1 RNA rebound upon stopping antiretroviral therapy. AIDS 13(8): F59-62
6. Blankson JN, Persaud D, Siliciano RF. (2002). The challenge of viral reservoirs in HIV-1 infection. Annu. Rev. Med. 53: 557-93
7. Chun TW, Finzi D, Margolick J, et al. (1995). In vivo fate of HIV-1-infected T cells: quantitative analysis of the transition to stable latency. Nat. Med. 1(12): 1284-90
8. Finzi D, Hermankova M, Pierson T, et al. (1997). Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 278(5341): 1295-300
9. Wei X, Ghosh SK, Taylor ME, et al. (1995). Viral dynamics in human immunodeficiency virus type 1 infection. Nature 373(6510): 117-22
10. Perelson AS, Essunger P, Cao Y, et al. (1997). Decay characteristics of HIV-1-infected compartments during combination therapy. Nature 387(6629): 188-91
11. Siliciano RF, Greene WC. (2011). HIV latency. Cold Spring Harb. Perspect. Med. 1(1): a007096
12. Siliciano JD, Kajdas J, Finzi D, et al. (2003). Long-Term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat. Med. 9(6): 727-28
13. Crooks AM, Bateson R, Cope AB, et al. (2015). Precise quantitation of the latent HIV-1 reservoir: implications for eradication strategies. J. Infect. Dis. pii: jiv218
14. Dinoso JB, Kim SY, Wiegand AM, et al. (2009). Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy. PNAS 106(23): 9403-8
15. Gandhi RT, Zheng L, Bosch RJ, et al. (2010). The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial. PLOS Med. 7(8): e1000321
16. Guadalupe M, Reay E, Sankaran S, et al. (2003). SevereCD4+T-cell depletion in gut lymphoid tissue during primary human immunodeficiency virus type 1 infection and substantial delay in restoration following highly active antiretroviral therapy. J. Virol. 77(21): 11708-17
17. Chun TW, Nickle DC, Justement JS, et al. (2008). Persistence of HIV in gut-Associated lymphoid tissue despite long-Term antiretroviral therapy. J. Infect. Dis. 197(5): 714-20
18. Valcour V, Sithinamsuwan P, Letendre S, Ances B. (2011). Pathogenesis of HIV in the central nervous system. Curr. HIV/AIDS Rep. 8(1): 54-61
19. Walter BL, Wehrly K, Swanstrom R, et al. (2005). Role of low CD4 levels in the influence of human immunodeficiency virus type 1 envelope V1 and V2 regions on entry and spread in macrophages. J. Virol. 79(8): 4828-37
20. Gartner S, Markovits P, Markovitz DM, et al. (1986). The role of mononuclear phagocytes in HTLVIII/LAV infection. Science 233(4760): 215-19
21. Brown A, Zhang H, Lopez P, et al. (2006). In vitro modeling of the HIV-macrophage reservoir. J. Leukoc. Biol. 80(5): 1127-35
22. Calantone N, Wu F, Klase Z, et al. (2014). Tissuemyeloid cells in SIV-infected primates acquire viralDNA through phagocytosis of infected T cells. Immunity 41(3): 493-502
23. Sigal A, Baltimore D. (2012). As good as it gets? The problem of HIV persistence despite antiretroviral drugs. Cell Host Microbe 12(2): 132-38
24. Jolly C, Kashefi K, Hollinshead M, Sattentau QJ. (2004). HIV-1 cell to cell transfer across an Env-induced, actin-dependent synapse. J. Exp. Med. 199(2): 283-93
25. Sigal A, Kim JT, Balazs AB, et al. (2011). Cell-To-cell spread of HIV permits ongoing replication despite antiretroviral therapy. Nature 477(7362): 95-98
26. Hill AL, Rosenbloom DI, Fu F, et al. (2014). Predicting the outcomes of treatment to eradicate the latent reservoir for HIV-1. PNAS 111(37): 13475-80
27. Dieffenbach CW, Fauci AS. (2011). Thirty years of HIV and AIDS: future challenges and opportunities. Ann. Intern. Med. 154(11): 766-71
28. Eisele E, Siliciano RF. (2012). Redefining the viral reservoirs that prevent HIV-1 eradication. Immunity 37(3): 377-88
29. Hutter G, Nowak D, Mossner M, et al. (2009). Long-Term control of HIV by CCR5 delta32/delta32 stem-cell transplantation. N. Engl. J. Med. 360(7): 692-98
30. Liu R, Paxton WA, Choe S, et al. (1996). Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 86(3): 367-77
31. Henrich TJ, Hanhauser E, Marty FM, et al. (2014). Antiretroviral-free HIV-1 remission and viral rebound after allogeneic stem cell transplantation: report of 2 cases. Ann. Intern. Med. 161(5): 319-27
32. Persaud D, Gay H, Ziemniak C, et al. (2013). Absence of detectableHIV-1 viremia after treatment cessation in an infant. N. Engl. J. Med. 369(19): 1828-35
33. Luzuriaga K, Gay H, Ziemniak C, et al. (2015). Viremic relapse after HIV-1 remission in a perinatally infected child. N. Engl. J. Med. 372(8): 786-88
34. Martinez-Bonet M, Puertas MC, Fortuny C, et al. (2015). Establishment and replenishment of the viral reservoir in perinatally HIV-1-infected children initiating very early antiretroviral therapy. Clin. Infect. Dis. 61(7): 1169-78
35. Chun TW, Stuyver L, Mizell SB, et al. (1997). Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. PNAS 94(24): 13193-97
36. Buckheit RW 3rd, Allen TG, Alme A, et al. (2012). Host factors dictate control of viral replication in two HIV-1 controller-chronic progressor transmission pairs. Nat. Commun. 3: 716
37. Blankson JN, Bailey JR, Thayil S, et al. (2007). Isolation and characterization of replication-competent human immunodeficiency virus type 1 from a subset of elite suppressors. J. Virol. 81(5): 2508-18
38. Metcalf Pate KA, Pohlmeyer CW, Walker-Sperling VE, et al. (2015). A murine viral outgrowth assay to detect residual HIV type 1 in patients with undetectable viral loads. J. Infect. Dis. 212(9): 1387-96
39. Saez-Cirion A, Lacabaratz C, Lambotte O, et al. (2007). HIV controllers exhibit potentCD8Tcell capacity to suppress HIV infection ex vivo and peculiar cytotoxic T lymphocyte activation phenotype. PNAS 104(16): 6776-81
40. Emu B, Sinclair E, Hatano H, et al. (2008). HLA class I-restricted T-cell responses may contribute to the control of human immunodeficiency virus infection, but such responses are not always necessary for long-Term virus control. J. Virol. 82(11): 5398-407
41. Saez-Cirion A, Bacchus C, Hocqueloux L, et al. (2013). Post-Treatment HIV-1 controllers with a long-Term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI study. PLOS Pathog. 9(3): e1003211
42. Moir S, Buckner CM, Ho J, et al. 2010.Bcells in early and chronicHIV infection: evidence for preservation of immune function associated with early initiation of antiretroviral therapy. Blood 116(25): 5571-79
43. Hunt PW, Brenchley J, Sinclair E, et al. (2008). Relationship between T cell activation and CD4+ T cell count inHIV-seropositive individuals with undetectable plasmaHIVRNAlevels in the absence of therapy. J. Infect. Dis. 197(1): 126-33
44. Crowell TA, Gebo KA, Blankson JN, et al. (2015). Hospitalization rates and reasons among HIV elite controllers and persons with medically controlled HIV infection. J. Infect. Dis. 211(11): 1692-702
45. Strain MC, Little SJ, Daar ES, et al. (2005). Effect of treatment, during primary infection, on establishment and clearance of cellular reservoirs of HIV-1. J. Infect. Dis. 191(9): 1410-18
46. Jain V, Hartogensis W, Bacchetti P, et al. (2013). Antiretroviral therapy initiated within 6 months of HIV infection is associated with lower T-cell activation and smaller HIV reservoir size. J. Infect. Dis. 208(8): 1202-11
47. Chun TW, Justement JS, Moir S, et al. (2007). Decay of theHIV reservoir in patients receiving antiretroviral therapy for extended periods: implications for eradication of virus. J. Infect. Dis. 195(12): 1762-64
48. Whitney JB, Hill AL, Sanisetty S, et al. (2014). Rapid seeding of the viral reservoir prior to SIV viraemia in rhesus monkeys. Nature 512(7512): 74-77
49. Margolick JB, Imteyaz H, Gallant JE, et al. (2010). Prolonged viral suppression without therapy in an HIV-1 seroconverter following early antiretroviral therapy and daily interleukin-2. AIDS 24(6): 932-35
50. Deeks SG. (2012). HIV: shock and kill. Nature 487(7408): 439-40
51. Xing S, Siliciano RF. (2013). Targeting HIV latency: pharmacologic strategies toward eradication. Drug Discov. Today 18(11-12): 541-51
52. Manson McManamy ME, Hakre S, Verdin EM, Margolis DM. (2014). Therapy for latentHIV-1 infection: the role of histone deacetylase inhibitors. Antivir. Chem. Chemother. 23(4): 145-49
53. Bartholomeeusen K, Fujinaga K, Xiang Y, Peterlin BM. (2013). Histone deacetylase inhibitors (HDACis) that release the positive transcription elongation factor b (P-TEFb) from its inhibitory complex also activate HIV transcription. J. Biol. Chem. 288(20): 14400-7
54. Wei DG, Chiang V, Fyne E, et al. (2014). Histone deacetylase inhibitor romidepsin induces HIV expression in CD4 T cells from patients on suppressive antiretroviral therapy at concentrations achieved by clinical dosing. PLOS Pathog. 10(4): e1004071
55. Archin NM, Liberty AL, Kashuba AD, et al. (2012). Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature 487(7408): 482-85
56. Cillo AR, Sobolewski MD, Bosch RJ, et al. (2014). Quantification of HIV-1 latency reversal in resting CD4+ T cells from patients on suppressive antiretroviral therapy. PNAS 111(19): 7078-83
57. Shan L, Deng K, Shroff NS, et al. (2012). Stimulation ofHIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation. Immunity 36(3): 491-501
58. Esparza J. (2013). A brief history of the global effort to develop a preventive HIV vaccine. Vaccine 31(35): 3502-18
59. West AP Jr, Scharf L, Scheid JF, et al. (2014). Structural insights on the role of antibodies in HIV-1 vaccine and therapy. Cell 156(4): 633-48
60. Chun TW, Murray D, Justement JS, et al. (2014). Broadly neutralizing antibodies suppress HIV in the persistent viral reservoir. PNAS 111(36): 13151-56
61. Caskey M, Klein F, Lorenzi JC, et al. (2015). Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117. Nature 522(7557): 487-91
62. Halper-Stromberg A, Lu CL, Klein F, et al. (2014). Broadly neutralizing antibodies and viral inducers decrease rebound from HIV-1 latent reservoirs in humanized mice. Cell 158(5): 989-99
63. Vaccari M, Poonam P, Franchini G. (2010). Phase III HIV vaccine trial in Thailand: a step toward a protective vaccine for HIV. Expert Rev. Vaccines 9(9): 997-1005
64. Kim JH, Excler JL, Michael NL. (2015). Lessons from the RV144 Thai phase III HIV-1 vaccine trial and the search for correlates of protection. Annu. Rev. Med. 66: 423-37
65. Hansen SG, Ford JC, Lewis MS, et al. (2011). Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature 473(7348): 523-27
66. Hansen SG, Piatak M Jr, Ventura AB, et al. (2013). Immune clearance of highly pathogenic SIV infection. Nature 502(7469): 100-4
67. Manjunath N, Yi G, Dang Y, Shankar P. (2013). Newer gene editing technologies towardHIVgene therapy. Viruses 5(11): 2748-66
68. Tebas P, Stein D, Tang WW, et al. (2014). Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. N. Engl. J. Med. 370(10): 901-10
69. Zhu W, Lei R, Le Duff Y, et al. (2015). The CRISPR/Cas9 system inactivates latent HIV-1 proviral DNA. Retrovirology 12: 22
70. Hu W, Kaminski R, Yang F, et al. (2014). RNA-directed gene editing specifically eradicates latent and prevents new HIV-1 infection. PNAS 111(31): 11461-66
71. Joseph A, Zheng JH, Follenzi A, et al. (2008). Lentiviral vectors encoding human immunodeficiency virus type 1 (HIV-1)-specific T-cell receptor genes efficiently convert peripheral blood CD8 T lymphocytes into cytotoxic T lymphocytes with potent in vitro and in vivo HIV-1-specific inhibitory activity. J. Virol. 82(6): 3078-89
72. Siliciano JD, Siliciano RF. (2005). Enhanced culture assay for detection and quantitation of latently infected, resting CD4+ T-cells carrying replication-competent virus in HIV-1-infected individuals. Methods Mol. Biol. 304: 3-15
73. Ho YC, Shan L, Hosmane NN, et al. (2013). Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure. Cell 155(3): 540-51
74. Rouzioux C, Melard A, Avettand-Fenoel V. (2014). Quantification of total HIV1-DNA in peripheral blood mononuclear cells. Methods Mol. Biol. 1087: 261-70
75. Strain MC, Lada SM, Luong T, et al. (2013). Highly precise measurement of HIV DNA by droplet digital PCR. PLOS ONE 8(4): e55943
76. Eriksson S, Graf EH, Dahl V, et al. (2013). Comparative analysis of measures of viral reservoirs in HIV-1 eradication studies. PLOS Pathog. 9(2): e1003174
77. Laird GM, Eisele EE, Rabi SA, et al. (2013). Rapid quantification of the latent reservoir for HIV-1 using a viral outgrowth assay. PLOS Pathog. 9(5): e1003398
78. Shan L, Rabi SA, Laird GM, et al. (2013). A novel PCR assay for quantification of HIV-1 RNA. J. Virol. 87(11): 6521-25
79. Bullen CK, Laird GM, Durand CM, et al. (2014). New ex vivo approaches distinguish effective and ineffective single agents for reversing HIV-1 latency in vivo. Nat. Med. 20(4): 425-29
80. Strategies forManagement of Antiretroviral Therapy (SMART) Study Group, El-Sadr WM, Lundgren J, et al. 2006.CD4+count-guided interruption of antiretroviral treatment. N. Engl. J.Med. 355(22): 2283-96
81. Fox Z, Phillips A, Cohen C, et al. (2008). Viral resuppression and detection of drug resistance following interruption of a suppressive non-nucleoside reverse transcriptase inhibitor-based regimen. AIDS 22(17): 2279-89
82. Rothenberger MK, Keele BF, Wietgrefe SW, et al. (2015). Large number of rebounding/founder HIV variants emerge from multifocal infection in lymphatic tissues after treatment interruption. PNAS 112(10): E1126-34